Latest News



June 3, 2020 0
It is great to have a campaign that lasts. Too many advertisers change their ad executions too quickly. Consumers benefit by seeing a good campaign kept on air. It takes a long time to establish brand recall and keeping continuity of a campaign helps with brand and ad awareness.

Cosentyx, from Novartis, is one of my favorites as an enduring campaign for psoriasis. It is not the only one. Humira also has done a good job over the years. Cosentyx is particularly good at finding a memorable theme. They found a few words to headline their integrated media message. “See Me” and “Watch Me” are four words that convey the essence of their message over the last four years.

It is very easy for DTC brands to want to advertise all their benefits and over complicate the message. Consumers want the bottom-line benefit in language they can understand and remember. Cosentyx found the emotional cue so important in good advertising. In the initial ad back in 2016, Cosentyx showed real sufferers who felt they were judged by their disease and visible symptoms. They wanted people to see them and not their disease.

This “See Me” was therefore born as an enduring psoriasis campaign. Cyndi Lauper was added to the mix of real sufferers which was an interesting celebrity use. Usually a celebrity gets their own ad but, in this case, Cosentyx added Cyndi to the mix of regular folks.

Cosentyx has stuck with the “See Me” message in all media formats. It is successfully adopted in print, digital, and video. Cyndi Lauper is still integrated into the mix of real patients four years later. She is not the star of the ads, just a memorable celebrity who is one of many sufferers profiled. 

Cosentyx figured out that psoriasis makes sufferers feel more than physical problems. The condition creates an emotional separation as patients feel other people see the disease, not the person behind it. This is a brilliant insight that makes the ads so effective. I do not expect this idea will ever become old and Cosentyx can run with the “See Me” and “Watch Me” for years longer.

The latest psoriatic arthritis ads use “Watch Me” as the main tag. They show real patients who have had enduring relief and are saying watch me control this disease. The takeaway is that Cosentyx has been around long enough to be a trusted drug that works. I applaud Novartis and their agency Hill Holliday Health for creating a campaign that is enduring and unique.
Bob Ehrlich
Chairman
DTC Perspectives, Inc.

Bob Ehrlich


May 28, 2020 0
Rinvoq, a new drug for Rheumatoid Arthritis (RA), is on my creative radar this week. The AbbVie drug has an interesting 60 second spot that debuted earlier this year. There are several elements that I think are done quite well. First, the benefits are well explained with a voice over and supers for emphasis. Second, there is a clear demo of how RA attacks the body. Third, and I think most unique for DTC, is how the fair balance is introduced. 

Fair balance is often presented as a quick voice over and supers that sometimes is confusing because it is integrated with the benefit discussion. In Rinvoq, there is a clear transition between the benefits and fair balance. At exactly the 30 second mark a new voice over announcer takes over. The benefit section has a female announcer and the fair balance is voiced by a male voice. I am not sure this has been done before but clearly the consumer is helped by such a distinct transition in voice overs.

Research has shown that fair balance is actually seen positively by consumers. Therefore, why not do what Rinvoq does by clearly presenting the risks and side effects instead of trying to hurry through them as many ads do? Consumers deserve to hear the balance in the same tone and manner as benefits. It gives them reassurance that the drug maker is not trying to confuse them or minimize the risks.

I also like the logo of a swirl that is part of the brand name super. Having some logo to aid brand recall is important. It can give consumers an alternate way to describe the band to physicians. It also can connect the brand identification in print and digital media. Memorable devices used in the past, like the Prilosec Purple Pill and the walking bladder from Myrbetriq, exemplify the idea of alternate brand identification.

Rinvoq shows an ad can add unique elements while still using a fairly standard DTC approach. This vignette approach is done in most DTC ads because the drug industry is heavily constrained by FDA regulations and by nature formulaic. Here we have scenes of a female photographer on safari and a female renovating a house with a sledgehammer. These are probably not what most RA sufferers do,but Rinvoq is trying to show strenuous activities are possible after taking Rinvoq to control RA.

So I guess you can say a meat and potatoes creative approach can still be unique when you add in interesting visual and voice elements. In this case, Rinvoq has created an excellent ad by adding in interesting elements throughout including the oft neglected fair balance portion.
Bob Ehrlich
Chairman
DTC Perspectives, Inc.

Bob Ehrlich


May 20, 2020 0
Dear DTC Colleague,

The first campaign I have chosen to discuss is corporate. Normally I will focus on brand or disease information campaigns. In this case and at this time, however, it is highly appropriate to discuss the new Pfizer spot on research for COVID-19 which first aired April 15. The campaign is a powerful statement on what research scientists at Pfizer and other private and public institutions are doing to battle COVID-19.

The 60 second campaign is themed around the phrase “Science Will Win.” The creative device here is showing vignettes of scientists conducting research. An authoritative announcer narrates the reassuring story that society has faced disease and pandemics in the past and won and will again. What is very interesting is the term Coronavirus or COVID-19 is never said. The ad starts with scenes of people with masks and empty store shelves. We don’t really need to hear the disease name as it is obvious to all of us what the ad is referencing.

“With Science Will Win, we sought to create hope by reinforcing our commitment to scientific collaboration and our pledge to use our resources to battle against and ultimately end the pandemic,” Pfizer’s Dana Gandsman, Senior Director, Reputation Communications told DTC Perspectives.

Why is this ad good? At a time when the Pharma industry is facing so much criticism over the price of drugs, it is inspiring to hear that the drug makers are likely to give us hope for an eventual return to normalcy. The role of drug makers as heroic saviors of mankind may have seemed disingenuous to many Americans in the past. When PhRMA ran its excellent industry campaign a few years ago promoting its research it was probably seen cynically by many critics. Industry has argued that clinical research will suffer under price controls. That argument was difficult to make successfully as politicians and consumer advocates constantly criticized drug company pricing and profits.

The new Pfizer ad is coming at a time when industry probably does have the admiration and support of most Americans. Pfizer does not try to explicitly promote its own company in this ad. In fact the only company mention is in the super at the end of the ad. Pfizer has been in the news for its COVID-19 vaccine development with a German partner and the possibility of a vaccine available by year end.

Drug makers have a huge opportunity to drastically change their image. Gilead just donated all of its existing Remdesivir doses, the first drug proven to treat COVID-19. I am sure a vaccine will be priced very favorably and will not be a huge financial win for the drug industry. Will Bernie Sanders still hate us? Yes, but hearing him still talk about drug company profiteers seems odd and out of touch. The lesson from COVID-19 is we need the power and, yes, profitability of private industry to keep us safe.

Pfizer and Grey, who is the agency behind this ad, deserve credit for producing an ad that gives accolades to every research scientist at all of the companies working on cures. This is not a time for self-promotion as we are truly all in this together. Will ads like these change the feeling about drug companies? I expect that if one of these companies produces an affordable vaccine or cure within a year the image will improve dramatically. Will consumers get back to complaining about high drug prices? They will, but drug companies will build up a lot of goodwill if normalcy returns because their investment in science won over the virus.
Bob Ehrlich,
Chairman
DTC Perspectives, Inc.

Bob Ehrlich